Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PALIVIZUMAB Cause Incorrect product administration duration? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Incorrect product administration duration have been filed in association with PALIVIZUMAB (Synagis). This represents 0.1% of all adverse event reports for PALIVIZUMAB.

6
Reports of Incorrect product administration duration with PALIVIZUMAB
0.1%
of all PALIVIZUMAB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Incorrect product administration duration From PALIVIZUMAB?

Of the 6 reports, 2 (33.3%) required hospitalization.

Is Incorrect product administration duration Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PALIVIZUMAB. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does PALIVIZUMAB Cause?

Respiratory syncytial virus infection (1,692) Pyrexia (1,055) Death (856) Bronchiolitis (724) Cough (665) Pneumonia (657) Dyspnoea (466) Nasopharyngitis (462) Vomiting (445) Influenza (398)

What Other Drugs Cause Incorrect product administration duration?

ETONOGESTREL (3,974) POLYETHYLENE GLYCOL 3350 (2,129) NIRMATRELVIR\RITONAVIR (744) DOCOSANOL (634) LANSOPRAZOLE (564) LOPERAMIDE (543) NAPROXEN (499) INSULIN LISPRO (479) DICLOFENAC (362) OMEPRAZOLE (302)

Which PALIVIZUMAB Alternatives Have Lower Incorrect product administration duration Risk?

PALIVIZUMAB vs PALONOSETRON PALIVIZUMAB vs PAMIDRONATE PALIVIZUMAB vs PAMIDRONIC ACID PALIVIZUMAB vs PANCRELIPASE PALIVIZUMAB vs PANCRELIPASE AMYLASE\PANCRELIPASE LIPASE\PANCRELIPASE PROTEASE

Related Pages

PALIVIZUMAB Full Profile All Incorrect product administration duration Reports All Drugs Causing Incorrect product administration duration PALIVIZUMAB Demographics